The EAEU Quality Document is one of the regulatory concepts that international pharmaceutical teams most often underestimate.
It is not simply a Russian translation of the finished-product specification. It is not a laboratory SOP. It is not a replacement for CTD Module 3.
It is a region-specific regulatory document that expresses the approved quality-control position of the medicinal product in a form used through release, shelf life and regulatory quality assessment.
The Eurasian Economic Commission describes the Quality Document as specific to the EAEU region and based on the specifications for the medicinal product and its relevant materials. The current drafting framework is established by EEC Board Decision No. 151 and the revised guidance introduced by Decision No. 137 of 4 October 2022.
For a foreign manufacturer, the central question is therefore:
Can the quality position already supported by our global CMC dossier be translated into an EAEU Quality Document that is internally consistent, scientifically justified, workable for expert laboratory assessment and maintainable after approval?
That is a regulatory-integration task, not a formatting exercise.
The Quality Document sits between Module 3 and regulatory control
CTD Module 3 contains the full pharmaceutical-development and quality justification.
The Quality Document does something different: it consolidates the approved control position that will be used for regulatory quality purposes during the medicinal product’s lifecycle.
This makes it an interface between:
global CMC dossier → EAEU expert assessment → laboratory testing → approved product → post-approval variations.
If that interface is poorly designed, contradictions become visible quickly.
A method can be scientifically justified in Module 3 but described differently in the Quality Document. A specification can be updated globally but not propagated into the EAEU lifecycle. A pharmacopoeial reference can become obsolete. A quality limit can be copied from a historical national document although the current CTD supports another control strategy.
The value of the Quality Document is therefore in creating one controlled regulatory position.
Do not start by translating an old national normative document
Many products entering the EAEU have legacy quality documents from Russia or another member state.
Those documents can be useful historical sources, but they should not automatically become the master for the EAEU Quality Document.
The correct starting point is the current technical dossier:
- what is actually manufactured;
- what is actually tested;
- what Module 3 currently supports;
- what stability data support through shelf life;
- what pharmacopoeial framework applies;
- what expert laboratory will need to understand and reproduce.
Pharegis therefore performs a regulatory reconciliation before authoring the document.
The Quality Document should not contradict the commercial control strategy
A common portfolio problem is that several “truths” coexist:
- global corporate specification;
- site release specification;
- shelf-life specification;
- CTD 3.2.P.5;
- legacy Russian/national quality document;
- EAEU Quality Document draft;
- method actually used by QC.
These documents may have evolved at different times.
The regulatory project should establish which differences are legitimate and which represent uncontrolled dossier drift.
Pharegis maps the current and proposed EAEU position and identifies where the manufacturer needs document correction, scientific justification, pharmacopoeial alignment, variation work or a deliberate regulatory decision rather than silent harmonization.
Pharmacopoeial alignment is a strategy, not a citation exercise
The Pharmacopoeia of the Eurasian Economic Union is part of the common quality framework and continues to develop.
The EEC Pharmacopoeial Committee maintains and expands the Union Pharmacopoeia, while the Commission has also published methodological guidance to support harmonized preparation of pharmacopoeial texts, specifications and Quality Documents.
For a manufacturer, “pharmacopoeial alignment” should answer practical questions:
- which compendial framework governs the proposed control;
- whether the current global method is acceptable in the EAEU context;
- whether a pharmacopoeial method can be used directly or requires appropriate justification/verification;
- whether the global and EAEU terminology describe the same quality attribute;
- whether a future pharmacopoeial update can trigger dossier/lifecycle work.
Pharegis does not use pharmacopoeial alignment to redesign a manufacturer’s global QC system unnecessarily.
The objective is to identify the minimum regulatory adaptation required for a defensible EAEU position.
The 2022 Quality Document guidance was built around real expert-laboratory experience
When updating the Quality Document guidance in 2022, the EEC stated that the revision reflected accumulated experience of EAEU laboratories performing quality assessment during registration and industry feedback from dossier submissions.
That is an important signal for applicants.
The Quality Document should be written for regulatory use, not merely to mirror corporate documentation.
A document that looks elegant but leaves the expert laboratory unable to understand the approved control logic creates avoidable questions and delays.
Expert laboratory readiness should be assessed before submission
For medicinal-product registration, quality expertise can include laboratory testing and assessment of the reproducibility of quality-control methods.
The Quality Document and supporting Module 3 package should therefore be reviewed together with the practical testing package.
The manufacturer should know before filing whether the expert organization will have access to the required method documentation, reference materials, necessary clarifications and supporting evidence needed to reproduce the intended quality assessment.
The purpose is not to transfer the manufacturer’s internal QC operation to the expert laboratory.
It is to remove hidden dependencies that can stop the registration quality assessment.
The Quality Document is a lifecycle document
After approval, the Quality Document does not freeze the product permanently.
Manufacturing processes, analytical methods, pharmacopoeial requirements, specifications, shelf-life evidence and sites can change.
A technical change should therefore be assessed for its effect on:
Module 3 → Quality Document → official testing position → variation classification → implementation.
This is particularly important for multinational manufacturers because global CMC changes can reach different markets on different dates.
Without a controlled EAEU impact assessment, the manufacturer can end up releasing commercial product under one global specification while the EAEU dossier still reflects an earlier control position.
The Quality Document can reveal CMC debt before the regulator does
Preparing or reviewing the document is often diagnostically useful.
It can expose:
- old methods retained in the registration dossier after the site moved to a new method;
- inconsistent release and shelf-life positions;
- a specification that does not match the stability programme;
- outdated pharmacopoeial references;
- differences among national dossiers being consolidated into an EAEU dossier;
- missing justification for a control historically accepted without modern CTD rationale;
- manufacturing/site changes not fully propagated into the dossier.
Those findings are not “Quality Document errors”. They are evidence that the underlying regulatory baseline needs repair.
This is why Pharegis uses Quality Document work as part of CMC due diligence and dossier remediation.
A good Quality Document should be precise without becoming unnecessarily complicated
Overcomplication creates regulatory risk as well as operational cost.
Every additional bespoke requirement can create additional validation burden, reference-material dependency, expert-laboratory complexity, future variation burden or supply risk.
At the same time, oversimplification can fail to control an important quality attribute adequately.
The objective is therefore not to make the document “as detailed as possible”.
It is to make the approved control position scientifically justified, reproducible and proportionate to product risk.
The Quality Document should be developed together with the registration pathway
For a new EAEU registration, the quality-document strategy should be aligned early with:
- CMC gap assessment;
- reference-state strategy;
- sample/reference-standard planning;
- expert-laboratory testing;
- EAEU GMP status;
- expected pre-filing manufacturing changes.
For a post-2025 dossier-alignment case, it should also be reconciled against legacy national quality documents and the final EAEU dossier baseline.
For a variation, the Quality Document may need to be updated as part of the same technical change package.
It should not be left as a document to be “prepared at the end”.
Value for global regulatory and CMC teams
A strong global CMC organization already owns the scientific control strategy.
Pharegis does not need to replace that expertise.
Our value is to translate the global technical position into the EAEU regulatory framework and identify where local expert practice creates a specific interface.
That normally means:
- preserving the manufacturer’s scientifically justified global approach where possible;
- identifying EAEU-specific documentary requirements;
- reconciling pharmacopoeial differences;
- preventing contradictions between Module 3 and the Quality Document;
- anticipating expert-laboratory questions;
- keeping future variations manageable.
This is a narrower and more useful task than rewriting the manufacturer’s quality system.
Where Quality Document projects most often fail
Common failure modes include:
- translating a legacy national normative document without reconciling it to the current CTD;
- treating the Quality Document as a duplicate of 3.2.P.5;
- allowing global specifications and the EAEU dossier to drift apart;
- using pharmacopoeial references without checking current applicability;
- creating unnecessary bespoke controls that become permanent lifecycle burden;
- failing to plan critical testing dependencies for expert assessment;
- changing a method globally without assessing EAEU variation impact;
- harmonizing contradictory national specifications by editorial compromise rather than scientific/regulatory decision;
- leaving the Quality Document until the final weeks before filing.
These problems are avoidable if the document is treated as a regulatory control interface from the beginning.
What Pharegis manages in an EAEU Quality Document project
Typical deliverables include:
- Quality Document / CTD consistency review;
- legacy national-to-EAEU quality-position reconciliation;
- high-level CMC control-strategy gap matrix;
- pharmacopoeial alignment assessment;
- Quality Document authoring or remediation under Decisions No. 151/137;
- expert-laboratory readiness review;
- testing-dependency map;
- coordination of technical questions with the manufacturer’s QC/CMC team;
- dossier-query response support;
- variation-impact assessment for future quality changes;
- lifecycle version-control plan.
The technical depth is adapted to the product and project. The objective is not to impose a generic local specification template on a mature global product.
Discuss an EAEU Quality Document / CMC alignment project
For an initial assessment, prepare the current Module 3 dossier, current global specifications, existing national/EAEU Quality Documents if any, pharmacopoeial basis, analytical-method package, manufacturing/testing sites, planned CMC changes and the target registration/variation procedure.
Pharegis can then determine whether the existing control strategy can be carried into the EAEU dossier directly, where regulatory adaptation is required and which issues should be resolved before quality expertise begins.
The objective is not to create another specification. It is to establish one usable EAEU quality position that remains consistent with the global CMC dossier, regulatory testing and future product lifecycle.
Regulatory basis
- EEC Board Decision No. 151 of 7 September 2018 — Guideline on Drafting the Medicinal Product Quality Document.
- EEC Board Decision No. 137 of 4 October 2022 — current major revision of the Quality Document guideline.
- EEC Council Decision No. 78 of 3 November 2016 — EAEU registration and expert-examination rules.
- EEC Board Decision No. 100 of 11 August 2020 — Pharmacopoeia of the Eurasian Economic Union and subsequent pharmacopoeial development.
- EAEU Pharmacopoeial Committee methodological guidance published in 2025 on harmonized preparation of pharmacopoeial texts, specifications and Quality Documents.
Regulatory status reviewed: August 2026.